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Abstract: Migraine is a chronic neurological condition with episodic exacerbations. Migraine 
is highly prevalent, and associated with signiﬁ  cant pain, disability, and diminished quality of 
life. Migraine management is an important health care issue. Migraine management includes 
avoidance of trigger factors, lifestyle modiﬁ  cations, non-pharmacological therapies, and medica-
tions. Pharmacological treatment is traditionally divided into acute or symptomatic treatment, 
and preventive treatment or prophylaxis. Many migraine patients can be treated using only acute 
treatment. Patients with severe and/or frequent migraines require long-term preventive therapy. 
Prophylaxis requires daily administration of anti-migraine compounds with potential adverse 
events or contraindications, and may also interfere with other concurrent conditions and treat-
ments. These problems may induce patients to reject the idea of a preventive treatment, leading 
to poor patient adherence. This paper reviews the main factors inﬂ  uencing patient acceptance 
of anti-migraine prophylaxis, providing practical suggestions to enhance patient willingness to 
accept pharmacological anti-migraine preventive therapy. We also provide information about the 
main clinical characteristics of migraine, and their negative consequences. The circumstances 
warranting prophylaxis in migraine patients as well as the main characteristics of the compounds 
currently used in migraine prophylaxis will also be brieﬂ  y discussed, focusing on those aspects 
which can enhance patient acceptance and adherence.
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Introduction
Migraine can be regarded as a chronic neurological condition with episodic exacerba-
tions. Migraine is highly prevalent, and associated with signiﬁ  cant pain, disability, 
and diminished quality of life. Thus, migraine management is an important health 
care issue.
Different elements need to be considered in migraine management. They include: 
avoidance of trigger factors, lifestyle modiﬁ  cations, non-pharmacological therapies, 
and medications. Pharmacological treatment is traditionally divided into acute or symp-
tomatic treatment, and preventive treatment or prophylaxis. Many migraine patients 
can be treated using only acute treatment, that is, prescribing medications that are used 
only during headache attacks to abort an ongoing attack or to stop its progression to 
severe pain and associated symptoms. Patients with severe and/or frequent migraines 
require long-term preventive therapy.
Prophylaxis requires daily administration of anti-migraine compounds, whether 
or not a migraine attack is occurring. All the drugs used for migraine prevention have 
potential and often relevant adverse events or contraindications, and may also interfere 
with other concurrent conditions and treatments. These problems may induce patients 
to reject the idea of a preventive treatment, or may lead to poor patient adherence.
This paper reviews the main factors inﬂ  uencing patient acceptance of anti-migraine 
prophylaxis, providing some practical suggestions to enhance patient’s willingness Neuropsychiatric Disease and Treatment 2008:4(6) 1156
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to accept pharmacological anti-migraine preventive therapy. 
We also provide information about the main clinical char-
acteristics of migraine and on the negative consequences of 
this condition. The circumstances warranting prophylaxis 
in migraine patients as well as the main characteristics of 
the compounds currently used in migraine prophylaxis will 
also be brieﬂ  y discussed, focusing on those aspects which 
can enhance patient acceptance and adherence
Migraine overview
Clinical presentation of migraine
Migraine is an idiopathic headache disorder with a high 
prevalence globally (Stewart et al 1994; Launer et al 1999; 
Roncolato et al 2000; Lipton et al 2001; Henry et al 2002; 
Wang 2003; Steiner 2003; Lipton et al 2007). About 6% 
to 8% of men and 12% to 14% of women meet criteria for 
migraine. The disorder is characterized by episodes of moder-
ate to severe head pain, which is often unilateral and pulsat-
ing, and typically aggravated by routine physical activities. 
The duration of untreated migraine attacks is rather long, 
from 4 hours to 3 days (median duration 18 hours). Pain is 
accompanied by autonomic symptoms, the most common 
being nausea, vomiting, photophobia, and phonophobia 
(Headache Classiﬁ  cation Subcommittee of the International 
Headache Society 2004). Other symptoms, such as osmopho-
bia, pallor, fatigue, difﬁ  cult in concentration, blurred vision, 
or diarrhea, can be present.
In many patients the headache phase is preceded by 
premonitory symptoms (or prodromes) which can last from 
a few hours to 24 hours, and are characterized by fatigue, 
yawning, ﬂ  uid retention, mood changes, sensory hypersensi-
tivity, food cravings, or increased thirst (Blau 1984). Similar 
psychological, general and autonomic symptoms may also 
characterize the resolution phase of an attack (postdrome) 
(Blau 1980).
For up to 25% of migraineurs, the headache phase can be 
preceded by transient focal neurological symptoms, generally 
lasting from 4 minutes to 1 hour, deﬁ  ned as migraine aura. 
The most common aura symptoms are visual disturbances 
(scintillating scotomata, hemianopia, blind spots), sensory dis-
turbances (unilateral paresthesias affecting the face and limbs, 
numbness), or speech/language disturbances (dysarthria, apha-
sia). Uncommon aura phenomena include weakness, ataxia, 
vertigo, or loss of consciousness (Headache Classiﬁ  cation Sub-
committee of the International Headache Society 2004). The 
median migraine attack frequency is one per month, although 
about 30% of sufferers in the general population report three 
or more attacks per month (Lipton et al 2007).
Some attacks are unpredictable, but in most patients 
several factors which are able to trigger migraine attacks are 
evident (Silberstein 1990). Migraine triggers include dietary 
factors (such as hunger, alcohol, and chocolate), hormonal 
changes (menstruation), environmental factors (such as 
bright lights, odors, and altitude), physical activities (sex, 
sports), and psychological and chronobiological changes 
(stress, sudden anxiety or joy, too much or too little sleep, 
schedule changes).
There is a wide variability in the features and in the fre-
quency of attacks, as well as in the burden of disease on the 
individual (Stewart et al 1994). This variation depends on 
constitutional and environmental factors and on coexisting 
conditions, and explains why therapeutic needs differ among 
patients and often in the same patient at different periods of 
his or her life, justifying tailored migraine management.
Inﬂ  uence of migraine on functioning 
and on quality of life
The signiﬁ  cant reported clinical characteristics of migraine, 
and the fact that its prevalence and incidence peak in middle 
life when an individual is likely to be more actively engaged 
in work, social and family duties, explains why migraine 
can cause a signiﬁ  cant negative impact on patient lives 
(Stewart et al 1994; Roncolato et al 2000; Lipton et al 2001; 
Henry et al 2002; Lipton et al 2007). Numerous studies have 
demonstrated that migraine is very disabling, often causing 
severe functional impairment during attacks.
The majority of people with migraine in the general 
population sampled in the population-based second American 
Migraine Study (AMS II) (Lipton et al 2001) experienced 
some form of functional impairment. Fifty-three percent 
reported that their severe headaches led to substantial impair-
ment of daily activities and bed rest in many cases, while 1 of 
every 3 migraineurs missed at least 1 day of work or school 
in the 3 months prior to the survey.
For 264 consecutive migraine patients at an Italian 
Headache Center (D’Amico et al 2004), all daily activities 
were reportedly impaired. The mean values obtained in this 
survey indicated that over the 3-month period preceding 
the survey, total or partial impairment due to migraine was 
evident in all daily duties. The mean values obtained in 
this survey indicated that ability to perform housework and 
personal and social activities were affected by migraine on 
14.5 days/3 months (household work missed on 4.3 days; 
household signiﬁ  cantly impaired on 4.6 days; social, lei-
sure and family duties skipped on 5 days). During the same 
period of time, total or partial disability affected patients’ Neuropsychiatric Disease and Treatment 2008:4(6) 1157
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occupational activities on a mean of 8.8 days/3 months, with 
2.2 days of absenteeism (ie, days with absence from work or 
from school because of attacks), and 6.6 days of presenteeism 
(ie, patients experiencing a signiﬁ  cant reduction in work or 
school productivity because of migraine attacks while they 
were at work or at school) (D’Amico et al 2004).
A telephone survey with 6-month recall conducted in 
Israel and eight European countries on young women with 
migraine, who were employed or full-time students, showed 
that during the prior 6 months, 46% of participants missed 
at least 1 day of work or school, and 74% were prevented 
from functioning fully at work or school because of migraine. 
Mean work/school absenteeism due to migraine was 1.9 days 
over 6 months (range, 0.8–2.8 days). More than 60% of 
young migraineurs reported one or more occurrences of being 
unable to spend time with family and friends or unable to 
enjoy recreational activities (Dueland et al 2004).
The pervasive disruption of migraine on all daily duties 
was conﬁ  rmed in French surveys on the general population 
(Lucas et al 2005; Lucas et al 2006). In population-based 
surveys from the USA and UK (Lipton et al 2003), 85% 
of migraineurs living with a partner reported substantial 
reduction during migraine in their ability to do household 
work. Forty-ﬁ  ve percent were forced to miss social, fam-
ily, and leisure activities, and 32% avoided making plans 
for fear of cancellation due to possible occurrence of a 
migraine attack. In the same studies, 50% of the interviewed 
migraineurs believed that they were more likely to argue 
with their partners and children, and many of them reported 
a negative inﬂ  uence of the disorder on time spent with their 
children and partners, reporting elements of disharmony 
and conﬂ  ict in their families because of migraine (such as 
deciding not to have children or delaying having children). 
Negative consequences on work performances, time spent in 
family activities, difﬁ  culty in communication and, as noted, 
tendency to argue with partners were also reported by the 
household partners of individuals with migraine.
Migraine can cause signiﬁ  cant life style changes. Besides 
family engagements, education, employment choices and 
achievements may also be curtailed both by unpredictable 
attacks and by the tendency of migraineurs to avoid certain situ-
ations which involve the risk of triggering a migraine attack.
In addition, these factors lead to a negative impact of 
migraine in between attacks. Numerous studies have con-
ﬁ  rmed that migraineurs experience a poor quality of life and 
diminished feelings of well-being even during the pain-free 
intervals. Studies performed in different countries, either 
on individuals from the general population or on patients 
from headache clinics, reveal that migraine is associated 
with signiﬁ  cantly lower scores on various health-related 
quality-of-life rating scales, regardless of age, gender, or 
socioeconomic status (Osterhaus et al 1994; Monzón and 
Lainez 1998; Terwindt et al 2000; D’Amico et al 2004; 
Lucas et al 2006). Patients with migraine report disturbances 
of sleep and contentment, and experience greater emotional 
distress compared to non-migraine subjects (Dahlof and 
Dimenas 1995). Health-related quality of life in migraineurs 
is worse than that observed in people without migraine, and 
it appears to be similar in physical functions, and even worse 
in social and emotional domains, than in people with other 
chronic disorders, such as myocardial infarction, diabetes, 
hypertension, and asthma (Osterhaus et al 1994; Terwindt 
et al 2000).
Preventive therapy in migraine 
patients
Indications and goals of prophylaxis
While acute treatment is generally indicated in all 
migraineurs, prophylaxis is indicated only in selected cases. 
The universally accepted goal of prophylaxis is a reduction in 
migraine frequency. It is important to note that in recent years 
it has become clear that this aspect cannot be the only indica-
tor of treatment success and patient satisfaction (Silberstein 
for the US Headache Consortium 2000; Dowson et al 2004; 
Sheftell et al 2004; Members of the task force EFNS 2006; 
D’Amico and Lanteri-Minet 2006; Diamond et al 2006).
International evidence-based guidelines from the US 
Headache Consortium (Silberstein SD for the US Head-
ache Consortium 2000) and the European Federation of 
Neurological Societies (EFNS) (Members of the task force 
EFNS 2006) have focused on the circumstances warranting 
preventive treatment in migraineurs. Besides a high mean 
monthly number of attacks, a decision to start a preventive 
treatment in an individual migraineur must be guided by the 
effectiveness of acute therapy in that individual, the risk of 
medication overuse, by his/her preference to start a daily 
treatment, and, above all, by the impact of the condition on 
a patient’s daily life (Tables 1, 2).
Appropriate prophylaxis can reduce the global burden of 
migraine. D’Amico et al (2006) showed that both ability to 
perform daily activities (assessed by MIDAS), and health-
related quality of life (investigated by SF-36) can improve 
signiﬁ  cantly in migraine patients receiving different currently 
used preventive drugs for a period of three months. Data from 
controlled trials with topiramate in migraine prophylaxis Neuropsychiatric Disease and Treatment 2008:4(6) 1158
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suggest that quality of life was better in treated patients, when 
measured with a generic questionnaire (SF-36) and with a 
migraine-speciﬁ  c tool (MSQ) (Brandes et al 2006; Dahlof 
et al 2007), and also that disability might be reduced when 
patients received this drug for periods of 6 to 14 months 
(Diener et al 2007).
General principles of prophylaxis
Typically, preventive drugs must be used for periods of 
months. International guidelines suggest a minimum trial 
of 2 to 3 months of daily administration, which in fact is the 
shortest time period needed to assess clinically relevant effects 
on the condition (Silberstein for the US Headache Consortium 
2000; Members of the task force EFNS 2006). Although there 
is not a general agreement on the ideal duration of each prophy-
laxis period, recently published data suggest greater opportu-
nity with longer treatment periods. The efﬁ  cacy of topiramate 
in migraine prevention was maintained when this compound 
was administered continuously for up to 14 months (Diener 
et al 2007). In another study, the efﬁ  cacy of topiramate was 
further increased when prophylaxis was continued for rather 
long periods (Rapoport et al 2006). When a group of migraine 
patients were treated for 8 months in an open-label extension 
phase after two large double-blind, placebo-controlled trials 
of 26 weeks duration, the mean number of headache attacks 
decreased from 3.4 +/− 2.6 per month in patients treated with 
topiramate (at the end of the double-blind treatment periods) 
to 2.2 ± 2.4 per month after completion of the open-label phase 
with the active drug (Rapoport et al 2006).
Available compounds 
for anti-migraine prophylaxis
In 2000, the US Headache Consortium published techni-
cal reports and guidelines on preventive medications for 
migraine. (Silberstein for the US Headache Consortium 2000: 
Ramadan et al 2000). These reports evaluated preventive 
agents by strength of evidence, scientiﬁ  c effect measures, 
and clinical impression of effect. These evaluations were 
collected into groups as seen in Table 3.
Since this publication, evidence for topiramate in the ﬁ  rst 
group, and several other medications that would properly 
be placed in Group 2 have been published. These will be 
summarized below.
Mechanisms of action
Migraine is a generally inherited condition of neuronal 
hyperexcitability with a central generator, peripheral pain 
mechanisms, and central integration. Debate continues as to 
whether the generator for migraine is due to cortical spread-
ing depression (CSD), that is, is cortical in location and 
pathophysiology, or whether CSD occurs just in those with 
aura, while those without aura have the onset of migraine in 
a central brainstem periaquductal gray/dorsal raphe midbrain 
generator.
CSD begins with a slow activation of neurons and glia 
and associated hyperemia. This activation is in turn followed 
by a wave of neuronal depression, accompanied by oligemia. 
CSD activates brain matrix metalloproteinases (MMP), such 
as MMP-9, opening the blood brain barrier, which may be 
necessary for preventive medications accessing central brain 
compartments (Gursoy-Ozdemir et al 2004).
Ayata et al published a seminal paper in 2006, in which 
topiramate, valproate, propranolol, amitriptyline, methy-
sergide, saline, or D-propranolol (clinically ineffective for 
migraine and serving as a second placebo) were administered 
to rats either acutely or chronically over weeks and months. 
The impact of treatment was determined on the frequency of 
evoked CSDs after topical potassium application or on the 
incremental cathodal stimulation threshold to evoke CSD. 
Chronic daily administration of migraine prophylactic drugs 
dose-dependently suppressed CSD frequency by 40% to 80% 
Table 2 EFNS Task Force Guidelines (Members of the task force 
EFNS 2006): factors that indicate the opportunity of consider and 
discuss anti-migraine prophylaxis with the patient 
•   The quality of life, business duties, or school attendance are severely 
impaired
•  Frequency of attacks per month is two or higher
•  Migraine attacks do not respond to acute drug treatment
•  Frequent, very long, or uncomfortable auras occur
Table 1 US headache consortium guidelines: circumstances war-
ranting preventive medications in migraineurs (Silberstein 2000)
1.   Recurring migraine that signiﬁ  cantly interferes with the patient’s daily 
routine despite acute treatment (eg, two or more attacks a month 
that produce disability that lasts at least 3 days or headache attacks 
that are infrequent but produce profound disability);
2.   Failure, contraindication to, or troublesome side-effects from acute 
medications;
3.  Overuse of acute medications;
4.   Special circumstances, such as hemiplegic migraine or attacks with a 
risk of permanent neurological injury;
5.   Very frequent headaches (more than two a week), or a pattern of 
increasing attacks over time, with the risk of developing medication 
overuse headache or rebound with acute attack medicines;
6.   Patient preference, ie, the desire to have as few acute attacks as 
possible.Neuropsychiatric Disease and Treatment 2008:4(6) 1159
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and increased the cathodal stimulation threshold, whereas 
acute treatment was ineffective. Longer treatment durations 
produced stronger CSD suppression. Chronic D-propranolol 
treatment did not differ from saline control. The study sug-
gested that CSD may be the common therapeutic target 
for widely prescribed migraine prophylactic drugs (Ayata 
et al 2006).
Migraine pain itself is caused by neurogenic inﬂ  ammation 
and vasodilation in the meninges, sensitizing nociceptive affer-
ents. The central generator somehow activates these peripheral 
pain mechanisms, and migraine preventive agents likely share 
common inhibitory effects which decrease central neuronal 
hyperexcitability, making the initiation of these inﬂ  ammatory 
and vascular pain events less frequent and less severe.
Classes of migraine medications
Tricyclic antidepressants (TCAs)
Amitriptyline, a tertiary amine TCA, as noted in Table 4, 
has excellent quality of evidence for effect, 3+scientiﬁ  c 
and clinical impression of effect, and is in Group 1 of 
the US Headache Consortium Guidelines (Ramadan et al 
2000). Amitriptyline is registered as a migraine preventive 
medication in the UK, in Italy, and other countries, but not 
in the US.
Nortriptyline, protriptyline (tertiary amines), doxepin 
(secondary amine), and imipramine have clinical impression 
for efﬁ  cacy but no or limited randomized controlled trials 
(RCTs) (Ramadan et al 2000).
Adverse events associated with the use of TCAs are best 
described as “the four horsemen of the apocalypse”: dry 
mouth, constipation, sedation, and weight gain, the latter from 
antihistaminic effects. Dry mouth, constipation, tachycardia, 
blurry vision, and urinary retention are all anticholinergic 
side effects, maximal in the elderly. TCAs can lower the 
seizure threshold and can cause cardiac arrhythmias and 
orthostatic hypotension. Overdose is frequently lethal. TCAs 
can cause the syndrome of inappropriate ADH secretion 
(SIADH), and precipitate mania in bipolar patients.
Table 3 Preventive medications as listed by the US Headache Consortium (Ramadan et al 2000)
Group 1: 
Medium to high efﬁ  cacy, 
good strength of evidence, 
and a range of severity 
(mild to moderate) and 
frequency (infrequent to 
frequent) of side effects
Group 2: 
Lower efﬁ  cacy than 
those listed in ﬁ  rst 
column, or limited 
strength of evidence, 
and mild to moderate 
side effects
Group 3: 
Clinically efﬁ  cacious 
based on consensus and 
clinical experience, but 
no scientiﬁ  c evidence 
of efﬁ  cacy
Group 4: 
Medium to high 
efﬁ  cacy, good strength 
of evidence, but with 
side effect concerns
Group 5: 
Evidence indicating 
no efﬁ  cacy over 
placebo
Amitriptyline 
Divalproex sodium 
Lisuride*
Propranolol 
Timolol
Aspirin# 
Atenolol 
Cyclandelate* 
Fenoprofen 
Feverfew 
Flurbiprofen 
Fluoxetine (racemic) 
Gabapentin 
Guanfacine 
Indobufen* 
Ketoprofen 
Lornoxicam* 
Magnesium 
Mefenamic acid 
Metoprolol 
Nadolol 
Naproxen sodium 
Nimodipine 
Tolfenamic acid* 
Verapamil 
Vitamin B2
a. mild-to-moderate 
side effects
Cyproheptadine 
Bupropion 
Diltiazem 
Doxepin 
Fluvoxamine 
Ibuprofen 
Imipramine 
Mirtazepine 
Nortriptyline 
Paroxetine 
Protriptyline 
Sertraline 
Tiagabine 
Topiramate 
Trazodone 
Venlafaxine
b. (side effect concerns) 
Methylergonovine 
(methylergometrine) 
Phenelzine
Methysergide 
Flunarizine* 
Pizotifen* 
TR-DHE*
Acebutolol 
Alprenolol* 
Carbamazepine 
Clomipramine, 
Clonazepam 
Clonidine DEK* 
Femoxetine* 
Flumedroxone* 
Indomethacin 
Iprazochrome* 
Lamotrigine 
Mianserin* 
Nabumetone 
Nicardipine 
Nifedipine 
Oxprenolol* 
Oxitriptan* 
Pindolol 
Tropisetron* 
Vigabatrin*
#Does not include combination products.
*Currently not available in US.Neuropsychiatric Disease and Treatment 2008:4(6) 1160
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Maximizing treatment of comorbid illnesses would 
suggest selection of TCAs for use in patients with comorbid 
depression, sleep disturbance, or neck pain.
Beta blockers
Propranolol, a non-selective beta-blocker, has top level 
effectiveness and scientiﬁ  c evidence (Ramadan et al 2000), 
and is registered for migraine prevention in the US, UK, 
Italy, and other countries. Timolol, also non-selective, 
is also approved for migraine prevention in the US, and 
has almost as good evidence for efﬁ  cacy as propranolol 
(Ramadan et al 2000).
Nadolol, a non-selective beta-blocker, and atenolol 
and metoprolol, beta-1 selective beta-blockers are listed in 
Group 2 by the US Headache Consortium (Ramadan et al 
2000). The responder rate for beta blockers, those with at least 
a 50% reduction of migraine frequency, is 43% to 80%.
Quality of evidence and recommended daily doses are 
reported in Table 5. Beta blockers are relatively contraindi-
cated in patients with hypotension, congestive heart failure, 
asthma, Raynauds, depression, and diabetes mellitus.
Beta blockers should be considered in patients with 
comorbid hypertension or anxiety but not depression.
Calcium channel blockers
Flunarizine is the most widely used calcium channel blocker 
world wide. Although it is not available in the US, it is one 
of the most prescribed preventive drugs in Italy and in other 
European countries, as well as in Latin America. It is very 
effective clinically, with adequate, Grade B scientiﬁ  c evidence 
for 10 mg/day but the US Headache Consortium notes “side 
effect concerns, due to the risk of sedation, weight gain, 
depression, and extrapyramdal signs” (Ramadan et al 2000). 
These effects can be reduced by using the 5 mg/day dose.
Verapamil at 240 mg/day and diltiazem have similar 
level of scientiﬁ  c evidence to ﬂ  unarazine, with much less 
evidence of clinical effectiveness. The other calcium chan-
nel blockers have even less or no RCTs on which to rely 
(Ramadan et al 2000).
Some of the hemiplegic migraine subtypes and some 
patients with typical aura have been demonstrated to have 
calcium channelopathies, so that calcium channel blockers 
are more often selected in prevention for aura patients.
Cardiac effects from some calcium channel blockers 
(namely, from verapamil) are of concern, and may merit mon-
itoring of the QTc intervals on cardiograms. Also described 
are atrioventicular block, bradycardia, and arrhythmias. 
Constipation is common with verapamil, and hypotension, 
and peripheral edema may occur as well (Silberstein and 
Goadsby 2002).
Anti-epilepsy drugs (AEDs)
Valproate
Valproate has excellent scientiﬁ  c evidence, clinical effec-
tiveness, and is registered for migraine prevention in the 
US and other countries (not in Italy) for doses from 500 to 
1500 mg/day. The levels of scientiﬁ  c evidence and clinical 
evidence are reported in Table 6.
The limitations of valproate are its potential for serious 
adverse events. Teratogenicity, with neural tube defects 
occurs at a rate of 1% to 2%. In addition, polycystic ovarian 
syndrome occurred in 10.5% of female menstruating patients 
within one year of initiation of valproate treatment (Joffe 
et al 2006). The authors believe that valproate should not 
be used as a ﬁ  rst line treatment in migraine prevention for 
young, menstruating women.
Other common adverse events in order of occurrence are 
nausea, asthenia, and dyspepsia. Hepatotoxicity is common 
in children under 2 years old, but increases in likelihood in 
adults when valproate is co-administered with medications 
that induce the cytochrome p450 system such as barbi-
turates and benzodiazepines. Therefore, valproate is best 
Table 4 Tricyclic antidepressants (TCAs) in migraine prevention
TCA Recommended 
dose/day
US Headache 
Consortium 
Quality of 
evidence (*)
US Headache 
Consortium 
Clinical 
effectiveness (*)
Amitriptyline 30–150 mg A 3+
Nortriptyline 25–100 mg C 3+
Doxepin, 
Imipramine
30–150 mg C +
Protriptyline 10–40 mg C 2+
(*) Ratings from Ramadan et al 2000.
Table 5 Beta-blockers in migraine prevention
Beta blocker Recommended 
dose/day
US Headache 
Consortium 
Quality of 
evidence (*)
US Headache 
Consortium 
Clinical 
Effectiveness (*)
Propranolol 80–240 mg A 3+
Timolol 20–30 mg A 2+
Atenolol 100 mg B 2+
Nadolol 80–240 mg B 3+
Metoprolol 200 mg B 3+
(*) Ratings from Ramadan et al 2000.Neuropsychiatric Disease and Treatment 2008:4(6) 1161
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administered in prophylaxis as monotherapy. Other adverse 
events of concern include alopecia, tremor, and weight gain. 
Since valproate can rarely cause thrombocytopenia, other 
bone marrow dysfunction, and pancreatitis, in addition to the 
hepatic problems, blood monitoring is recommended.
Gabapentin
Gabapentin has adequate scientiﬁ  c evidence for effectiveness 
at 2400 mg/day based on one RCT. It has a propensity for 
causing drowsiness and dizziness, but no drug–drug interac-
tions, and is excreted unchanged in the urine (Mathew et al 
2001). The levels of scientiﬁ  c evidence and clinical evidence, 
and the recommended daily dose, are reported in Table 6.
Topiramate
Topiramate has excellent scientiﬁ  c evidence and clinical 
evidence for effectiveness, and is registered for migraine 
prevention in the US and most countries with 100 mg the 
optimal dose (Brandes et al 2004; Silberstein et al 2004). 
The levels of scientiﬁ  c evidence and clinical evidence are 
reported in Table 6.
CNS side effects are the most worrisome adverse events 
with topiramate use and include language problems, memory 
difﬁ  culty, and decreased concentration. Other serious adverse 
events include rare narrow angle-closure glaucoma early in 
treatment, hyperchloremic acidosis in 10% of patients, 
nephrolithiasis at a rate of 1% due to carbonic anhydrase 
inhibition, and rare oligohydrosis, which can result in fatal 
hyperthermia, more frequently in younger age groups at 
higher doses (Ziad et al 2005).
Around half of patients treated with topiramate will experi-
ence paresthesias. Weight loss, usually a welcome side effect, 
occurred in 9% of patients at 100 mg, the optimal dose, and 
the mean weight loss in those losing weight over a year was 
3%. Other side effects can include fatigue and diarrhea.
Anti-serotonin drugs
Two commonly used medications that block serotonin 
(5-HT)2 receptors are cyproheptadine (available in the US 
and some countries) and pizotifen (not available in the US, 
but available in most European countries, including Italy). 
Both are described by the US Headache Consortium as 
having “medium to high efﬁ  cacy, good strength of evidence, 
but with side effect concerns”, namely weight gain and 
drowsiness (Ramadan et al 2000). The dose for cyprohepta-
dine is 4 to 12 mg/day, for pizotifen, 1.5 to 6 mg/day.
Two other 5-HT2 antagonists are ergots, methysergide 
and methylergonovine or methylergometrine, its active 
metabolite. Evidence for the former is excellent, for the 
latter anecdotal.
These long acting ergots are less commonly used in 
migraine prevention due to the fact that triptans cannot be 
used as acute treatment in patients on ergots preventively 
and due to the risk of idiosyncratic ﬁ  brosis in heart (includ-
ing valvular ﬁ  brosis and resultant regurgitation and heart 
failure), GI tract, and lung, which can occur in 1/1500 to 
1/5000 patients after 6 months of steady use of methysergide. 
The risk for ﬁ  brotic complications has been linked to 5-HT2B 
agonist effects, despite the overall hypothesis that these 
medications work as 5-HT2 antagonists (Roth et al 2007). 
The authors use drug holidays every 6 months based on the 
hope rather than any evidence that this will prevent ﬁ  brotic 
complications for both medications. Those patients on these 
medications chronically should be monitored with CT of 
abdomen and lungs, and echocardiography. The ﬁ  brotic risk 
is probably why methysergide is not longer available in the 
US and Italy.
Other side effects can include drowsiness, leg aches 
presumably from ergotism, and GI adverse events of nausea, 
pain, and diarrhea.
Doses are up to 6 mg/day for methysergide and up to 
0.6 mg/day for methylergonovine/methylergometrine.
Herbs, minerals, vitamins, and supplements
Petasites (butterbur root), magnesium, vitamin B2 (ribo-
ﬂ  avin), and coenzyme Q10 all have adequate second level 
randomized controlled scientiﬁ  c and clinical evidence for 
efﬁ  cacy. Doses are 150 mg/day of petasites, 400 to 600 mg/ 
day of chelated magnesium, 25 to 400 mg/day of vitamin B2, 
and 300 mg/day of coenzyme Q10. Adverse events include 
eructation and GI upset for petasites, diarrhea for magne-
sium, bright yellow urine and rash for vitamin B2, and rash 
with coenzyme Q10 (Lipton et al 2004; Sandor et al 2005; 
Tepper et al 2006).
Other preventive agents
There is second level evidence of effectiveness for aspirin, 
and certain NSAIDs such as naproxen and ketoprofen. 
The same level of evidence (eg, single RCTs, or multiple 
Table 6 AEDs in migraine prevention
AED Recommended 
dose/day
Level of scientiﬁ  c 
evidence
Level of clinical 
effectiveness
Valproate 500–1500 mg A 3+
Gabapentin 900–2400 mg B 2+
Topiramate 100 mg A 3+Neuropsychiatric Disease and Treatment 2008:4(6) 1162
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less deﬁ  nitive RCTs) exists for the angiotensin converting 
enzyme inhibitor lisinopril at 20 mg/day, the angiotensin 
receptor blocker candasartan at 16 mg/day, and for the sero-
tonin norepinephrine inhibitor venlafaxine at 150 mg/day.
Starting, selecting and using 
preventive medication
The decision to use daily preventive is based on a weigh-
ing of frequency of attacks and acute medication use on the 
one hand, and disability or impact on the other. As number 
of headache days increases and number of days in which a 
patient used acute medication increases, the risk of trans-
formation into daily headache also increases dramatically. 
At around 9 days of acute medication use per month, or 
10 days of headache per month, the risk for chroniﬁ  cation of 
headache becomes so great that daily preventive treatment 
becomes essential, to drive the number of headache days 
down, allowing for judicious use of acute treatments and 
preventing medication overuse headache (Scher et al 2003; 
Katsarava et al 2004; Bigal et al 2006).
Daily prevention can be initiated at far lower frequencies 
of headache if disability is high or response to acute medica-
tion poor. This can be the case when triptans and ergots are 
contraindicated due to vascular disease, a situation calling for 
earlier intervention with daily preventive medication.
Special circumstances in which the risk for adverse out-
comes from migraine appear signiﬁ  cant, such as prolonged 
aura, or when each attack carries profound impact, such as 
in hemplegic and basilar-type migraine, also necessitate daily 
preventive medication.
Silberstein and Goadsby suggest the following approaches 
to successful preventive treatment:
1.  Start the drug at a low dose.
2.  Give each treatment an adequate trial.
3.  Avoid interfering, overused, and contraindicated drugs.
4. Re-evaluate  therapy.
5.  Be sure that women of childbearing potential are aware 
of any potential risks.
6.  Involve patients in their care to maximize compliance.
7.  Consider comorbidity and choose medications to treat 
several coexisting disorders where possible.
8.  Choose a drug based on its proven efﬁ  cacy, the patient’s 
preferences and headache proﬁ  le, the drug’s side effects, 
and the presence or absence of coexisting or comorbid 
disease (Silberstein and Goadsby 2002).
Our own recommendations are:
1.  It is always best to try to select preventive medica-
tion calculated to treat multiple comorbid medical or 
psychiatric illnesses at the same time. Examples of this 
include migraine patients with sleep disturbance, depres-
sion, and neck pain, treated optimally with amitriptyline; 
or hypertension and anxiety, treated optimally with a 
beta blocker (Dowson et al 2003; Tepper et al 2004; 
Silberstein et al 2007).
2.  Do not forget that patients administered daily preventive 
medication must also be provided with acute medica-
tion, preferably migraine-speciﬁ  c. The severity of their 
migraine has led to the need for prophylaxis, they will 
have breakthrough migraines, and they must be given 
adequate as-needed treatment at the same time, with 
limits on usage to avoid medication overuse headache.
3.  Patients who have chronic daily headache or medication 
overuse headache, that is, headaches 15 days per month, 
will most likely respond neither to daily preventive 
medications nor triptans. Before initiation of preventive 
therapy, detoxiﬁ  cation is necessary; a failure to detoxify 
patients in medication overuse headache before starting 
preventive therapy is one of the most common reasons 
prophylaxis fails, along with starting at too high a dose, 
and failure to keep a patient on prevention for a long 
enough time.
Factors that can inﬂ  uence migraine 
patient acceptance of prophylaxis
Daily administration of preventive drugs
Patients might reject the idea of taking a pill each and every 
day, independently from the occurrence of their attacks. One 
reason for this is because they view migraine as an episodic 
disorder.
Physicians should communicate that, although char-
acterized by episodic attacks of head pain and associated 
symptoms, migraine is in fact a chronic condition. Care 
providers should provide some explanations about the biol-
ogy of migraine and the role of prophylaxis. They can make 
patients aware that migraine is a physiologic disorder with 
a constitutional predisposition and a particular susceptibility 
to develop the individual headache attacks when migraineurs 
are exposed to several biological and environmental trigger-
ing factors, and that consequently the condition may be par-
tially corrected by the use of preventive medications which 
can modulate this “neurochemical instability.”
Long duration of preventive therapy
Patients might not accept taking preventive drugs for periods 
of at least several months. Explanations on the nature of 
migraine as well as on the goals and the mechanisms of action Neuropsychiatric Disease and Treatment 2008:4(6) 1163
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of preventive compounds are required. This information 
should help patients to recognize that prophylaxis is by 
deﬁ  nition a long-term treatment, as its rationale is to gradu-
ally exert a positive action on the complex mechanisms 
causing migraine, and that the effect of prevention requires 
a regular and continuous administration for relatively long 
therapeutic cycles.
Deﬁ  nition and assessment of clinical 
outcomes
Some patients may expect that migraine prevention will fully 
eradicate their headaches. Others might think that their condi-
tion cannot be neither cured nor relieved by pharmacological 
interventions, and that they must “keep on suffering”, with 
no hope of improvement.
Physicians must inform patients that both of these con-
cepts are not correct. It is extremely important that care 
providers should provide realistic expectations for treatment 
outcomes, based on scientiﬁ  c evidence and on their own 
clinical experience. This means explaining that reduction 
in frequency is the primary goal, with spill over beneﬁ  ts on 
intensity and duration, as well as disability, but that acute 
attacks will still occur even with successful prophylaxis.
Physicians therefore should deliberately and clearly 
explain that scientiﬁ  c evidence shows that the drugs currently 
used in migraine prophylaxis are effective when compared to 
placebo, and that subjects on preventive compounds are likely 
to see a reduction in their headache episodes, as well as in 
their intensity and duration. It is important to share with them 
the main results of recent studies, indicating that prophylaxis 
is also able to restore their functioning in between attacks, 
by decreasing the negative effects of the condition on ability 
to perform daily activities and on quality of life.
As noted, patients must be carefully informed that 
complete disappearance of attacks cannot be expected after 
prophylaxis, and that analysis of data from the published 
literature indicates that about 45% of migraineurs receiving 
available preventive drugs will experience a reduction in the 
mean monthly frequency of their attacks of 50% or more, and 
around 20% of them will see a frequency reduction of 75% 
or more (Klapper 1997; Mathew et al 2001; Brandes et al 
2004; Diener et al 2004; Silberstein et al 2004).
Patients should be encouraged to keep a headache diary in 
order to record the occurrence of attacks during the treatment 
periods, inviting them to provide information also about the 
severity of pain and the degree of functional disability during 
their migraines. This will favor communication with their 
physician about the effectiveness of the ongoing treatment, 
and eventually indicate the need for adjusting daily doses or 
for changing the current preventive drug.
This line of communication could also be enhanced by 
the use of speciﬁ  c questionnaires to assess the impact of 
migraine on functioning and on the patient’s sense of well 
being. As noted above, clinicians should focus the attention 
of their patients on the fact that prophylaxis can eventually 
be useful in reducing migraine-related burden, and that 
reduction in disability and improvement in quality of life 
have been found in some clinical studies, and that these 
outcomes can be also be incorporated into clinical practice. 
In fact, clinicians can use speciﬁ  c questionnaires to assess 
the efﬁ  cacy of prophylaxis in a given patient. Among numer-
ous tools developed and tested in recent years, the Migraine 
Disability Assessment score (MIDAS) (Stewart et al 1999), 
and the Headache Impact test (HIT6) (Kosinski et al 2003) 
are suitable for clinical ofﬁ  ce use, as they are both simple, 
brief, self-administered, easy-to-score questionnaires.
MIDAS has ﬁ  ve questions assessing headache-related 
disability over the preceding 3 months, and can be sum-
marized in a single question: “How many days in the last 
3 months were you at least 50% disabled due to migraine at 
work, home, school, or recreational activities?” Each patient 
can be assigned to one of four disability levels, from grade I 
(corresponding to little or no disability) to grade IV (corre-
sponding to severe disability), on the basis of standardized 
intervals of the MIDAS total score which is obtained by the 
simple sum of the scores of the ﬁ  ve questions.
HIT6 includes 6 questions in different domains concern-
ing severity of pain, limitations in activities, tiredness, and 
mood changes related to migraine in the past four weeks. 
Each answer requires a rating on a 5-point scale (from never 
to always). Total score ranges from 36 to 78, with higher 
scores indicating a greater headache impact on patients. 
A score between 36 and 49 indicates little or no impact, 
a score of 60 or more indicates very severe headache-related 
impact.
Thus, both MIDAS and HIT6 may be very useful tools 
to verify the clinical situation from the patient point of view, 
providing a measurable insight on the global effect of pro-
phylaxis by simple paper-and-pencil questionnaires.
Efﬁ  cacy may be the most relevant factor guiding patient 
preferences in prevention. In a recent study (Peres et al 2007), 
72% of enrolled patients rated effectiveness as the most 
relevant positive aspect of prophylaxis, chosen from several 
factors. Furthermore, when patients were invited to choose 
among several different hypothetical prophylaxis scenarios 
(each one containing a simulation of 2 hypothetical headache Neuropsychiatric Disease and Treatment 2008:4(6) 1164
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preventive treatments with different characteristics), most of 
them were likely to select those preventive treatments with 
higher efﬁ  cacy rates, possibly with fewer adverse events, 
but still preferring treatments with higher efﬁ  cacy rates 
even if side effects were present. In this study (Peres et al 
2007), however, “efﬁ  cacy” might refer only to frequency 
reduction, and other aspects (such as changes in functioning 
and in quality of life, or in severity of pain or acute therapy 
efﬁ  cacy) were not explored.
Possibility of adverse events
The occurrence of adverse events following administration 
of preventive drugs is a very common concern expressed 
by migraine patients when they receive the prescription of 
prophylaxis. Concern for side effects may discourage suf-
ferers from accepting prophylaxis or may negatively inﬂ  u-
ence patient adherence, causing different problems, such as 
non regular daily dosing, self-reduction of the prescribed 
compound, or withdrawal of prophylaxis following trivial 
symptoms or events which are not treatment-related.
To overcome these problems, a comprehensive history 
taking should include: evaluation of life style (occupation, 
sports, time schedules, etc.) of the individual patient, eliciting 
fear of a particular adverse event, and obtaining history of 
occurrence of side effects from previous treatments. Clini-
cians should choose the preventive compound accordingly, 
with the active participation of their patient.
In any case, patients should be advised about the most 
common adverse events of the prescribed drugs and even of 
those uncommon effects which could be clinically relevant and 
which might require drug withdrawal. If possible, focus should 
be on the benign nature of most adverse events, the possibility 
that they could be reduced during the course of treatment, or 
that they could be minimized by reducing the daily doses.
The following scenarios can be regarded as practical 
examples. Compounds with a high risk of increasing weight 
(such as ﬂ  unarizine, valproate, or amitriptyline) should be 
avoided in a patient who is very concerned with weight gain. 
A drug which can cause difﬁ  culty in memory or speech slow-
ing (such as topiramate) should be not the ﬁ  rst choice in a 
patient who works as a teacher, or the possible occurrence of 
these effects should be communicated, instructing the patient 
to taper down the daily dose and eventually to stop treatment 
if these effects occur. Drugs which are likely to cause exces-
sive sedation or somnolence (such as amitriptyline) should 
not be prescribed to a taxi driver.
We suggest informing patients that symptoms such as par-
esthesias during topiramate treatment, mild somnolence with 
ﬂ  unarizine, or some nausea with sodium valproate should 
be regarded as substantially benign and often self-limiting 
or gradually vanishing adverse events: On the other hand, 
patients should be told to contact their physician if they expe-
rience visual disturbances, depression, or tremor while on 
topiramate, ﬂ  unarizine, or sodium valproate, respectively.
The recent survey among 250 patients from two headache 
centers in the US and in Brazil with primary headache diag-
noses (Peres et al 2007) suggests that fear of adverse events 
may be less relevant in patient preference and eventually in 
acceptance. Only 6% of the enrolled headache patients rated 
absence of adverse events as the most important aspect of pre-
vention when they were asked to rank a list of aspects which 
also included efﬁ  cacy, speed of onset, frequency of dosing, 
out-of-pocket expenses, and type of treatment (prescription/
vitamin). In this study (Peres et al 2007), however, only a few 
side effects were suggested for the patient evaluation, that is, 
weight gain, concentration difﬁ  culty, and fatigue.
In another study on a clinical sample (150 individuals 
with a history of migraine at a US headache center) (Rozen 
2006), migraine patients were asked to rank on a 1 to 10 scale 
some characteristics of preventive treatments. The second 
most highly ranked factor in terms of importance was that 
the prescribing clinician take time to explain the possible 
adverse events of the proposed medications. Again, data 
obtained in this sample suggest that migraine patients would 
accept a preventive treatment with a high side effect rate if it 
is effective. In the same study, possible effects on weight and 
the likelihood to cause sedation were indicated as important 
factors as to why patients (especially women) might not 
accept migraine prophylaxis.
Concluding remarks
The management of migraine is not a simple task, and clini-
cians should be aware that treatment strategies for migraine 
patients require that they understand and accept treatment 
decisions. Education is important for any therapeutic inter-
vention in migraine (such as acute therapy, avoidance of 
trigger factors, and non-pharmacological approaches), but 
may be particularly relevant when a long-term treatment 
plan, including preventive therapy, is prescribed.
In fact, prophylaxis requires a comprehensive evaluation 
of different aspects of a patient’s migraine and life style 
such as frequency and severity of attacks, response to acute 
therapy, quality of life and migraine-related functional dis-
ability, and life style and speciﬁ  c needs, to guide therapeutic 
decision, as well as to assess the outcome of the selected 
treatment. In this context, a patient’s acceptance of preventive Neuropsychiatric Disease and Treatment 2008:4(6) 1165
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therapy could be negatively inﬂ  uenced by several factors. 
Among these, reluctance to take medications every day and 
for long periods, concern about possible adverse events, and 
unrealistic expectations are the most common.
Clinicians must direct their efforts to help their patients 
accept prophylaxis, taking into account the following 
suggestions:
•  Differences in goals and treatment schedules between 
acute therapy (meant to address the immediate need for 
relief during an attack), and prophylaxis (whose main 
goals are to reduce the frequency of headache episodes 
as well as to limit the negative effects of migraine on 
daily life) should be clearly explained, in order to help 
patients understand that preventive drugs must be taken 
every day, and for long periods.
•  Accurate evaluation of the global clinical situation and 
life style of the individual patient should be performed.
•  The fact that the information given by the patient (par-
ticularly on those adverse events that could be intolerable 
and on the presence of concomitant conditions which 
might inﬂ  uence treatment course) has been taken into 
account to select the most appropriate prophylaxis must 
be communicated to the patient.
•  Active involvement of the individual patient in the 
assessment of prophylaxis outcomes during the treatment 
period should be reached, through the regular use of a 
headache diary and through the administration of speciﬁ  c 
disability/impact tools, with a consequent likely increase 
in the patient’s adherence with treatment schedule and 
satisfaction.
We agree with other authors (Rozen 2006; Manzoni and 
Torelli 2007) about the crucial role of the communication 
between patient and physician in the therapeutic manage-
ment of primary headaches. This is particularly true when 
preventive therapy is indicated, when the patient-physician 
interaction may count more than the characteristics of a single 
preventive compound.
Future research
While patient preference for acute migraine treatment has 
been extensively studied (Salonen et al 1999; Powers et al 
2000; Davies et al 2000; Sheftell et al 2004; Dowson et al 
2004; Goadsby et al 2004; Láinez et al 2006; Díez et al 2007), 
only three studies have been published on patient prefer-
ence for prophylaxis (Rozen 2006; Peres et al 2007; Kol 
et al 2008). Their results give an insight on patient attitudes 
and expectations in migraine prevention, but further studies 
are warranted to explore all the possible factors inﬂ  uencing 
patient acceptance, possibly in clinical samples and in 
population samples. Pharmacological research should be 
aimed at developing new preventive compounds with fewer 
adverse events in order to favor patient acceptance.
Another challenge for the near future is creating a more 
widespread awareness and knowledge about the importance 
of migraine as a public health problem. It has been well 
established that most people with migraine do not receive 
a correct diagnosis and are likely to be inadequately treated 
(Lipton et al 2001; Lipton et al 2003; MacGregor et al 2003; 
Lucas et al 2005; Lucas et al 2006; Diamond 2006; Lipton 
et al 2007). In surveys on the general population performed 
in France (Lucas et al 2006), in the US (Lipton et al 2007), 
and in the Netherlands (Terwindt et al 2000), the proportion 
of migraineurs not aware of their diagnosis ranged from 47% 
to 70%. Understandably, a corresponding underutilization of 
speciﬁ  c anti-migraine compounds, and particularly preven-
tive drugs, is evident in different countries. In fact, based 
on indications provided by international guidelines, up to 
38% to 50% of patients with migraine may be considered 
candidates for prevention (D’Amico and Lanteri-Minet 
2006; Lipton et al 2007), but only a minority of them are on 
prophylaxis (6% to 13% in population-based surveys) (Lucas 
et al 2005; Lipton et al 2007). Thus, a substantial proportion 
of migraine sufferers who might beneﬁ  t from prevention do 
not receive it, and it is likely that many of them would reject 
treatment due to the problems with acceptance of prophylaxis 
described above, further reducing the numbers of migraineurs 
appropriately treated.
More importantly, the authors believe that educational 
programs directed to health care professionals (such as pri-
mary care physicians, neurologists, nurse practitioners, and 
physician assistants) must be encouraged. Clinicians should 
be made aware that migraine is a clinically signiﬁ  cant disor-
der that, although generally benign, may cause disruption of 
individual patient lives, and that underdiagnosis and inap-
propriate treatment may cause increase in attack frequency, 
with consequent overuse of acute drugs, poor patient outcome 
and satisfaction. These factors are likely to increase the risk 
of migraine chroniﬁ  cation and of the development of medica-
tion overuse headache and chronic daily headache (Mathew 
et al 1982; Silberstein et al 1996; Scher et al 2003; Katsarava 
et al 2004). Chronic migraine, chronic daily headache, and 
medication overuse headache will, in turn, cause a more 
disabling burden on patient lives, and are more difﬁ  cult to 
treat (Monzón et al 1998; Meletiche et al 2001; Guitera et al 
2002; Bigal et al 2003; D’Amico et al 2003; D’Amico et al 
2004; D’Amico et al 2005; D’Amico et al 2008).Neuropsychiatric Disease and Treatment 2008:4(6) 1166
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Education should also be focused on the availability of 
the options for effective prophylaxis, as well as on emphasiz-
ing that good communication between physician and patient 
is the key factor in successful long-term therapy. Through 
this communication, patients can express their needs and 
become actively involved in the decision-making process of 
choosing whether to use migraine prophylaxis and how to 
select the most appropriate preventive compound. The active 
participation of patients improves acceptance of physician 
prescriptions. Of course, the role of the treating clinician 
is essential in each step of migraine management, putting 
into practice knowledge of published evidence and clinical 
experience, providing correct information and education, and 
setting realistic expectations for possible adverse events and 
for treatment goals in a given migraine patient.
Disclosures
Dr  D’Amico – in the last 5 years, grants and honoraria for par-
ticipating in meetings/congresses or Scientiﬁ  c Boards from 
AstraZeneca, Merck, Janssen-Cilag, GSK, OrthoMcNeil, 
Pﬁ  zer.
Dr Tepper: grants/research support from Allergan, 
Alexza, ANS/Advanced Bionics, AstraZeneca, Eisai, Endo, 
Forrest, GSK, King, Merck, Medtronix, Minster, Neurochem, 
NMT, Novartis, Nupathe, OrthoMcNeil, Pfizer, Pozen, 
Proethic, Takeda, Winston, Vernalis.
Consultant in last 5 years (only those marked 2007–2008 
current): Allergan (2007), AstraZeneca, Coherex (2008), 
Elan, Endo (2007–8), Forrest, GSK (2007–8), Merck 
(2007–8), NMT (2007–8), OrthoMcNeil (2007), Vernalis.
Speakers Bureau (only those marked 2007–2008 cur-
rent): Allergan, AstraZeneca, Endo (2007), GSK (2008), 
Merck (2008), NMT (2008), OrthoMcNeil (2007), Pﬁ  zer, 
Valeant (2008).
Advisors Board, 2007–8 GSK, Merck.
References
Ayata C, Jin H, Kudo C, et al. 2006. Suppression of cortical spreading 
depression in migraine prophylaxis. Ann Neurol, 59:652–61.
Bigal ME, Rapoport AM, Lipton RB, et al. 2003. Assessment of migraine 
disability using the migraine disability assessment (MIDAS) ques-
tionnaire: a comparison of chronic migraine with episodic migraine. 
Headache, 43:336–42.
Bigal ME, Lipton RB. 2006. Modiﬁ  able risk factors for migraine progres-
sion (or for chronic daily headaches) – clinical lessons. Headache, 
46 (Suppl 3):S144–6.
Blau JN. 1980. Migraine prodromes separated from the aura: Complete 
migraine. BMJ, 281:658–60.
Blau JN. 1984. Resolution of migraine attacks: Sleep and the recovery phase. 
J Neurol Neurosurg Psychiatry, 47:437–42.
Brandes JL, Saper JR, Diamond M, et al; for the MIGR-002 Study Group. 
2004. Topiramate for migraine prevention: a randomized controlled 
trial. JAMA, 291(8):965–73.
Brandes JL, Kudrow DB, Rothrock JF, et al. 2006. Assessing the ability 
of topiramate to improve the daily activities of patients with migraine. 
Mayo Clin Proc, 81(10):1311–9.
Dahlof CGH, Dimenas E. 1995. Migraine patients experience poorer sub-
jective well-being/quality of life even between attacks. Cephalalgia, 
15:31–6.
Dahlof C, Loder E, Diamond M, et al. 2007. The impact of migraine pre-
vention on daily activities: a longitudinal and responder analysis from 
three topiramate placebo-controlled clinical trials. Health Qual Life 
Outcomes, 4;5(1):56.
D’Amico D, Usai S, Grazzi L, et al. 2003. Quality of life and disability in 
primary chronic daily headaches. Neurol Sci, 24:S97–S100.
D’Amico D, Usai S, Grazzi L, et al. 2004. The impact of primary headaches 
on patients’ lives: Italian experience with the MIDAS and the SF-36 
questionnaires. Headache Care, 1:123–8.
D’Amico D, Grazzi L, Usai S, et al. 2005. Disability pattern in chronic 
migraine with medication overuse: a comparison with migraine without 
aura. Headache, 45:553–60.
D’Amico D, Lanteri-Minet M. 2006. Migraine preventive therapy: selection 
of appropriate patients and general principles of management. Expert 
Rev Neurother, 6:1147–57.
D’Amico D, Leone M, Grazzi L, et al. 2008. When should “chronic 
migraine” patients be considered “refractory” to pharmacological 
prophylaxis? Neurol Sci, 29(Suppl 1):S55–58.
Davies GM, Santanello N, Lipton RB. 2000. Determinants of patient satis-
faction with migraine therapy. Cephalalgia, 20:554–60.
Diamond ML, Wenzel RG, Nissan GR. 2006. Optimizing migraine therapy: 
evidence-based and patient-centered care. Expert Rev Neurother, 6:911–9.
Diez FI, Straube A, Zanchin G. 2007. Patient preference in migraine therapy. 
A randomized, open-label, crossover clinical trial of acute treatment of 
migraine with oral almotriptan and rizatriptan. J Neurol, 254:242–9.
Dowson AJ, Sender J, Lipscombe S, et al. 2003. Establishing principles for 
migraine management in primary care. Int J Clin Pract, 57:493–507.
Dowson AJ, Tepper SJ, Baos V, et al. 2004. Identifying patients who require 
a change in their current acute migraine treatment: the Migraine Assess-
ment of Current Therapy (Migraine-ACT) questionnaire. Current Med 
Res Opin, 20:1125–35.
Dowson AJ, Tepper SJ, Dahlof C. 2005. Patients’ preference for triptans and 
other medications as a tool for assessing the efﬁ  cacy of acute treatments 
for migraine. J Headache Pain, 6:112–20.
Diamond S, Bigal ME, Silberstein S, et al. 2007. Patterns of diagnosis 
and acute and preventive treatment for migraine in the United States: 
results from the American Migraine Prevalence and Prevention Study. 
Headache, 47:355–63.
D’Amico D, Solari A, Usai S, et al; for the Progetto Cefalee Lombardia 
Group. 2006. Improvement in quality of life and activity limitations 
in migraine patients after prophylaxis. A prospective longitudinal 
multicentre study. Cephalalgia, 26:691–96.
Diener HC, Tfelt Hansen P, Dahlof C, et al; for the MIGR-003 Study 
Group. 2004. Topiramate in migraine prophylaxis – results from a 
placebo-controlled trial with propranolol as an active control. J Neuro, 
251:943–50.
Diener HC, Agosti R, Allais G, et al; for the TOPMAT-MIG-303 Investiga-
tors Group. 2007. Cessation versus continuation of 6-month migraine 
preventive therapy with topiramate (PROMPT): a randomised, double-
blind, placebo-controlled trial. Lancet Neurol, 6:1054–62.
Dueland AN, Leira R, Burke TA, et al. 2004. The impact of migraine on 
work, family, and leisure among young women – a multinational study. 
Curr Med Res Opin, 20:1595–604.
Goadsby PJ, Dodick DW, Ferrari MD, et al. 2004. TRIPSTAR: prioritizing 
oral triptan treatment attributes in migraine management. Acta Neuro. 
Scand, 110:137–43.
Guitera V, Munoz P, Castillo J, et al. 2002. Quality of life in chronic daily 
headache: a study in a general population. Neurology, 58:1062–5.
Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, et al. 2004. Cortical 
spreading depression activates and upregulates MMP-9. J Clin Invest, 
113:1447–55.Neuropsychiatric Disease and Treatment 2008:4(6) 1167
Acceptance of migraine prophylaxis
Headache Classiﬁ  cation Subcommittee of the International Headache 
Society. 2004. The international classiﬁ  cation of headache disorders: 
2nd edition. Cephalalgia, 24(Suppl 1):1–160.
Henry P, Auray JP, Gaudin AF et al. 2002. Prevalence and clinical charac-
teristics of migraine in France. Neurology, 59:232–7.
Joffe H, Cohen LS, Suppes T, et al. 2006. Valproate is associated with 
new-onset oligoamenorrhea with hyperandrogenism in women with 
bipolar disorder. Biol Psychiatry, 59:1078–86.
Katsarava Z, Schneeweiss S, Kurth T, et al. 2004. Incidence and predictors 
for chronicity of headache in patients with episodic migraine. 
Neurology, 62:788–90.
Klapper J. 1997. Divalproex sodium in migraine prophylaxis: a dose-
controlled study. Cephalalgia, 17:103–38.
Kol CM, Dekker F, Neven AK, et al. 2008. Acceptance or rejection of pro-
phylactic medicine in patients with migraine: a cross-sectional study. 
Br J Gen Pract, 58:98–101.
Kosinski M, Bayliss MS, Bjorner JB, et al. 2003. A six-item short-form survey 
for measuring headache impact: the HIT-6. Qual Life Res, 12:963–74.
Lainez MJ, Evers S, Kinge E, et al. 2006. Preference for rizatriptan 10-mg 
wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. 
Cephalalgia, 26:246–56.
Launer LJ, Terwindt GM, Ferrari MD. 1999. The prevalence and characteris-
tics of migraine in a population-based cohort. Neurology, 53:537–42.
Lipton RB, Stewart WF, Diamond S, et al. 2001. Prevalence and burden 
of migraine in the United States: data from the American Migraine 
Study II. Headache, 41:646–57.
Lipton RB, Bigal ME, Kolodner K, et al. 2003. The family impact of 
migraine: population-based studies in the USA and UK. Cephalalgia, 
23:429–40.
Lipton RB, Sher AI, Steiner TJ, et al. 2003. Patterns of health care utilization 
for migraine in England and in the United States. Neurology, 60:441–8.
Lipton RB, Göbel H, Einhäupl KM, et al. 2004. Petasites hybridus root 
(butterbur) is an effective preventive treatment for migraine. Neurology, 
63:2240–4.
Lipton RB, Bigal ME, Diamond M, et al. 2007. AMPP Advisory Group. 
Migraine prevalence, disease burden, and the need for preventive 
therapy. Neurology, 68:343–9.
Lucas C, Chaffaut C, Artaz MA, et al. 2005. FRAMIG 2000: medical and ther-
apeutic management of migraine in France. Cephalalgia, 25:267–79.
Lucas C, Géraud G, Valade D, et al. 2006. Recognition and therapeutic 
management of migraine in 2004, in France: results of FRAMIG 3, a 
French nationwide population-based survey. Headache, 46:715–25.
MacGregor E A, Brandes J, Eikermann A. 2003. Migraine Prevalence and 
Treatment Patterns: The Global Migraine and Zolmitriptan Evaluation 
Survey. Headache, 43:19–26.
Manzoni CG, Torelli P. 2007. The patient–physician relationship in the 
approach to therapeutic management. Neurol Sci, 28:S130–S133.
Mathew NT, Stubits E, Nigam MR. 1982. Transformation of migraine into 
daily headache: analysis of factors. Headache, 22:66–8.
Mathew NT, Rapoport A, Saper J, et al. 2001. Efﬁ  cacy of gabapentin in 
migraine prophylaxis. Headache, 41:119–28.
Meletiche DM, Loﬂ  and JH, Young WB. 2001. Quality-of life differences 
between patients with episodic and transformed migraine. Headache, 
41:573–8.
Members of the task force: Evers S, Afra J, Frese A, et al. 2006. EFNS 
guideline on the drug treatment of migraine – report of an EFNS task 
force. Eur J Neurol, 13:560–72.
Monzón MJ, Láinez MJ. 1998. Quality of life in migraine and chronic daily 
headache patients. Cephalalgia, 18:638–43.
Osterhaus JT, Townsend RJ, Gandek B, et al. 1994. Measuring the functional 
status and well-being of patients with migraine headache. Headache, 
34:337–43.
Peres MF, Silberstein S, Moreira F, et al. 2007. Patients’ preference for 
migraine preventive therapy. Headache, 47:540–5.
Powers C, Szeto S, Pangtay D, et al. 2000. Evaluation of migraineurs’ 
preferences for naratriptan over conventional ﬁ  rst-line agents. Arch 
Fam Med, 9:753–8.
Ramadan NM, Silberstein SD, Freitag FG, et al. 2000. Evidence-based 
guidelines for migraine headache in the primary care setting: pharma-
cological management for prevention of migraine. Neurology, (serial 
on line) www.neurology.org.
Rapoport A, Mauskop A, Diener HC, et al. 2006. Long-term migraine 
prevention with topiramate: open-label extension of pivotal trials. 
Headache, 46:1151–60.
Roncolato M, Fabbri L, Recchia G, et al. 2000. An epidemiological study to 
assess migraine prevalence in a sample of Italian population presenting 
to their GPs. Eur Neurol, 43:102–6.
Roth BL. 2007. Drugs and valvular heart disease. N Engl J Med, 356:6–9.
Rozen TD. 2006. Migraine prevention: what patients want from medica-
tion and their physicians (a headache specialty clinic perspective). 
Headache, 46:750–3.
Salonen R, Ashford EA, Gibbs M, et al. 1999. Patient preference for oral 
sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: 
a double-blind, randomized, crossover study. Sumatriptan Tablets 
S2CM11 Study Group. Int J Clin Pract, (Suppl)105:16–22.
Sándor PS, Afra J, Ambrosini A, et al. 2000. Prophylactic treatment of migraine 
with beta-blockers and riboﬂ  avin: differential effects on the intensity 
dependence of auditory evoked cortical potentials. Headache, 40:30–5.
Scher AI, Stewart WF, Ricci JA, et al. 2003. Factors associated with the 
onset and remission of chronic daily headache in a population-based 
study. Pain, 106:81–9.
Sheftell FD, Feleppa M, Tepper SJ, et al. 2004. Patterns of use of triptans 
and reasons for switching them in a tertiary care migraine population. 
Headache, 44:661–8.
Silberstein SD, Silberstein MM. 1990. New concepts in the pathognesis of 
headache-Part II. Pain Manag, 3:334–42.
Silberstein SD, Lipton RB, Sliwinski M. 1996. Classiﬁ  cation of daily and 
near-daily headaches: ﬁ  eld trial of revised IHS criteria. Neurology, 
47:871–5.
Silberstein SD; for the US Headache Consortium. 2000. Practice parameter: 
Evidence-based guidelines for migraine headache (an evidence-based 
review). Report of the Quality Standars Subcommittee of the American 
Academy of Neurology. Neurology, 55:754–62.
Silberstein SD, Goadsby PJ. 2002. Migraine: preventive treatment. 
Cephalalgia, 22:491–512.
Silberstein SD, Neto W, Schmitt J, et al; and the MIGR-001 Study Group. 
2004. Topiramate in migraine prevention: results of a large controlled 
trial. Arch Neurol, 61:490–5.
Silberstein SD, Dodick D, Freitag F, et al. 2007. Pharmacological approaches 
to managing migraine and associated comorbidities – clinical consider-
ations for monotherapy versus polytherapy. Headache, 47:585–99.
Steiner TJ, Scher AI, Stewart WF, et al. 2003. The prevalence and disability 
burden of adult migraine in England and their relationships to age, 
gender and ethnicity. Cephalalgia, 23:519–27.
Stewart WF, Sheder AL, Simon D, et al. 1994. Migraine prevalence. A review 
of population-based studies. Neurology, 44(Suppl 4):S17–S23.
Stewart WF, Shechter A, Lipton RB. 1994. Migraine heterogeneity. Dis-
ability, pain intensity, and attack frequency and duration. Neurology, 
44(6 Suppl 4):S24–33.
Stewart WF, Lipton RB, Whyte J, et al. 1999. An international study to 
assess reliability of the Migraine Disability Assessment (MIDAS) 
score. Neurology, 53:988–94.
Tepper SJ, D’Amico D, Baos V, et al. 2004. Guidelines for prescribing 
prophylactic medications for migraine: a survey among headache 
specialists in different countries. Headache Care, 1:267–72.
Tepper SJ, Bigal, M, Rapoport A, Sheftell F. Alternative therapies: evidence 
based evaluation in migraine. Headache Care, 2006, 3:57–64.
Terwindt GM, Ferrari MD, Tijhuis M, et al. 2000. The impact of migraine 
on quality of life in the general population. Neurology, 55:624–9.
Wang SJ. 2003. Epidemiology of migraine and other types of headache in 
Asia. Curr Neurol Neurosci Rep, 3:104–8.
Ziad el K, Rahi AC, Hamdan SA, et al. 2005. Age, dose, and environmen-
tal temperature are risk factors for topiramate-related hyperthermia. 
Neurology, 65:1139–40.